BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, September 28, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Ozlo Sleepbuds

Bose veterans hear the sweet cha-ching of sound sleep in $10M series A

Aug. 8, 2023
By Shani Alexander
No Comments
Three former employees of Bose Corp. are banking on their audio experience and Ozlo Sleepbuds helping the millions of people who struggle to sleep soundly each night. That prospect is music to the ears of investors Lifearc Ventures and Artis Ventures, who led Ozlo Sleep Inc.’s $10 million round to bring the wireless, in-ear headphones to market in the next few weeks.
Read More

Med-tech market financings worth $1.62 billion each month in 2023

Aug. 7, 2023
By Amanda Lanier
No Comments
Med-tech companies raised $955 million from 40 transactions in July 2023, a decrease of 12.39% from the $1.09 billion raised in July 2022. The volume of med-tech financings has increased from 32 in July 2022, though it is less than the previous six months’ average of 43 and seven-month average of 42. Compared to prior years, July 2021 saw $4.78 billion raised in 74 financings, $3.15 billion from 80 transactions in July 2020 and $1.99 billion from 41 financings in July 2019.
Read More

Financings for Aug. 7, 2023

Aug. 7, 2023
No Comments
Biopharmas raising money in public or private financings, including: Adamis, Collegium, Cybin, Gracell, IO, Orgenics.
Read More
Mirxes stomach cancer blood test Gastroclear

Mirxes raises $50M in series D round for cancer early detection

Aug. 7, 2023
By Doris Yu
No Comments
Mirxes Holding Company Ltd. raised $50 million in a series D funding round to expand its cancer early detection blood tests, including its lead product stomach cancer blood test Gastroclear, in the Asia Pacific region. Mirxes uses RNA technology to develop diagnostic solutions for the early detection of diseases.
Read More
HKEX on phone, digital stock chart

Biologic cancer drug developer Sunho targets HK IPO

Aug. 4, 2023
By Marian (YoonJee) Chu
No Comments
On Aug. 3, Sunho Biologics Inc. filed to list on the Hong Kong Exchange, armed with its antibody and immunocytokine drug pipeline and post-investment valuation of ¥1.41 billion (US$196 million).
Read More

Financings for Aug. 4, 2023

Aug. 4, 2023
No Comments
Biopharmas raising money in public or private financings, including: Blue Water, Innocan.
Read More

Financings for Aug. 3, 2023

Aug. 3, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Tytocare, Voxneuro.
Read More

Financings for Aug. 3, 2023

Aug. 3, 2023
No Comments
Biopharmas raising money in public or private financings, including: Amber, Bio-Path, Kyverna, Mira, Nymox, X4.
Read More

Financings for Aug. 2, 2023

Aug. 2, 2023
No Comments
Biopharmas raising money in public or private financings, including: Adamis, Aptevo, Aridis, CG Oncology, Cyclo, Forte, Inozyme, Reglagene, Tarsus, Tonix.
Read More
Illustration of antibodies binding to human cell receptors
Immune

Forte Biosciences closes financing to advance lead product

Aug. 2, 2023
No Comments
Forte Biosciences Inc. has announced the closing of a $25 million financing to support the...
Read More
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 421 422 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 27, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing